Abstract P47: Harnessing Antineoplastic Properties of Artesunate for Prostate Cancer Therapy

作者
Chandra Sekhar Bhol,Muthu Kumaraswamy Shanmugam,Grace Chew,Goh Si Rui Eva,Sujit K. Bhutia,Gautam Sethi
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (15_Supplement): P47-P47
标识
DOI:10.1158/1538-7445.fcs2024-p47
摘要

Abstract Prostate cancer (PCa) is the most common cancer and a leading cause of cancer-related deaths among men globally, including in Singapore. The incidence of PCa has been increasing worldwide due to lifestyle changes, though there is a significant disparity in the incidence-to-mortality ratio between developed and developing countries, largely because of the advanced theragnostic approaches utilized in developed regions. While conventional treatments are effective for localized and metastatic PCa, treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC), a more aggressive form of the disease, remain poor with current therapies failing to significantly extend survival. Hence, in the current study we investigated the potential role of artesunate (ART), a semisynthetic derivative of the malaria drug artemisinin in PCa cell lines. Interestingly, the ART found to inhibit the cell growth, invasion, migration, stemness and trigger the expression of apoptosis and autophagy-related proteins in PCa cell lines. In particular, ART inhibited the expression of Wnt/β-catenin pathway proteins responsible for the progression of prostate cancer to mCRPC. Moreover, inhibiting the ART induced autophagy resulted in the survival of the PCa cells to a greater extent. Furthermore, the ART treatment in a preclinical model of prostate cancer exhibited a significant reduction of prostate tumor growth along with the inhibition of lung and liver metastasis. Overall, our findings suggest that ART may activate a powerful antitumor mechanism, offering a new therapeutic approach for treating mCRPC. Citation Format: Chandra Sekhar Bhol, Muthu Kumaraswamy Shanmugam, Grace Chew, Goh Si Rui Eva, Sujit Kumar Bhutia, Gautam Sethi. Harnessing Antineoplastic Properties of Artesunate for Prostate Cancer Therapy [abstract]. In: Proceedings of Frontiers in Cancer Science 2024; 2024 Nov 13-15; Singapore. Philadelphia (PA): AACR; Cancer Res 2025;85(15_Suppl):Abstract nr P47.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小化发布了新的文献求助10
1秒前
初心完成签到,获得积分10
2秒前
高石完成签到 ,获得积分10
2秒前
小明完成签到 ,获得积分10
7秒前
自觉夏彤完成签到,获得积分10
7秒前
曼曼完成签到,获得积分10
7秒前
糊涂的砖头完成签到,获得积分10
7秒前
TheSail完成签到,获得积分10
8秒前
甜美刺猬完成签到 ,获得积分10
8秒前
Tristan完成签到 ,获得积分10
10秒前
nkmenghan完成签到,获得积分10
10秒前
风趣的月光完成签到 ,获得积分10
10秒前
彤光赫显完成签到,获得积分10
10秒前
专一的白完成签到,获得积分10
12秒前
寒冷荧荧完成签到 ,获得积分10
12秒前
小巧的白竹完成签到,获得积分10
12秒前
马超放烟花完成签到,获得积分10
13秒前
浑天与发布了新的文献求助10
14秒前
遗传搬运工完成签到 ,获得积分10
15秒前
chengxue完成签到,获得积分10
16秒前
成就的大米完成签到 ,获得积分10
16秒前
三冬四夏完成签到 ,获得积分10
17秒前
陈祥完成签到 ,获得积分10
17秒前
tomcruise完成签到,获得积分10
17秒前
科研通AI6.4的应助被小化采纳,获得10
19秒前
和谐的sui完成签到,获得积分10
19秒前
xj完成签到 ,获得积分10
20秒前
cxjie320完成签到,获得积分0
22秒前
852的应助被科研通管家采纳,获得10
23秒前
lmy完成签到,获得积分10
23秒前
laq00519的应助被科研通管家采纳,获得10
23秒前
Akim的应助被科研通管家采纳,获得10
24秒前
坚强冰枫的应助被科研通管家采纳,获得10
24秒前
顾矜的应助被科研通管家采纳,获得10
24秒前
迪迦王完成签到,获得积分10
25秒前
贤惠的人龙完成签到,获得积分10
25秒前
小小青完成签到,获得积分10
25秒前
I2564完成签到,获得积分10
25秒前
SciGPT的应助被我想吃金鱼采纳,获得30
26秒前
Y_LH完成签到,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Sustainable Engineered Micro/Nanofibers and Hybrid Nanocomposites for Environmental Remediation 400
Ecotourism 400
Liquidus diagram and viscosity estimation in pseudo-binary system Li2B6O10–LiF 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8076070
求助须知:如何正确求助?哪些是违规求助? 9494166
关于积分的说明 21378678
捐赠科研通 7644097
什么是DOI,文献DOI怎么找? 3399993
关于科研通互助平台的介绍 2529768
邀请新用户注册赠送积分活动 2438679